Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains a Neutral rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and raises the price target from $47 to $48.
February 16, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico maintains a Neutral rating on Ultragenyx Pharmaceutical and raises the price target from $47 to $48.
The increase in price target by a reputable analyst like Laura Chico suggests a positive outlook on the stock's value, potentially leading to short-term investor optimism and a slight increase in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100